The fluoropyrimidine 5-fluorouracil (5-FU) that is tested as an anti-ovarian cancer drug in clinical protocols, inhibits the thymidylate synthase (TS) and interferes with DNA and RNA synthesis. This evidence concerns the gene TYMS and ovarian cancer.